Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96


Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.

Osses DF, Remmers S, Schröder FH, van der Kwast T, Roobol MJ.

Eur Urol. 2018 Nov 9. pii: S0302-2838(18)30851-0. doi: 10.1016/j.eururo.2018.10.053. [Epub ahead of print]


Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.


Prostate-specific antigen-based prostate cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.

Bokhorst LP, Bangma CH, van Leenders GJ, Lous JJ, Moss SM, Schröder FH, Roobol MJ.

Eur Urol. 2014 Feb;65(2):329-36. doi: 10.1016/j.eururo.2013.08.005. Epub 2013 Aug 11.


Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.

Roobol MJ, Kranse R, Bangma CH, van Leenders AG, Blijenberg BG, van Schaik RH, Kirkels WJ, Otto SJ, van der Kwast TH, de Koning HJ, Schröder FH; ERSPC Rotterdam Study Group.

Eur Urol. 2013 Oct;64(4):530-9. doi: 10.1016/j.eururo.2013.05.030. Epub 2013 May 25.


Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).

Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis L, Recker F, Berenguer A, Ruutu M, Kujala P, Bangma CH, Aus G, Tammela TL, Villers A, Rebillard X, Moss SM, de Koning HJ, Hugosson J, Auvinen A.

Eur Urol. 2009 Oct;56(4):584-91. doi: 10.1016/j.eururo.2009.07.018. Epub 2009 Jul 28.


Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, Kwiatkowski M, Recker F, Roobol MJ.

Eur Urol. 2012 Nov;62(5):745-52. doi: 10.1016/j.eururo.2012.05.068. Epub 2012 Jun 7.


Metastatic Prostate Cancer Incidence and Prostate-specific Antigen Testing: New Insights from the European Randomized Study of Screening for Prostate Cancer.

Buzzoni C, Auvinen A, Roobol MJ, Carlsson S, Moss SM, Puliti D, de Koning HJ, Bangma CH, Denis LJ, Kwiatkowski M, Lujan M, Nelen V, Paez A, Randazzo M, Rebillard X, Tammela TL, Villers A, Hugosson J, Schröder FH, Zappa M.

Eur Urol. 2015 Nov;68(5):885-90. doi: 10.1016/j.eururo.2015.02.042. Epub 2015 Mar 16.


Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.

Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schröder FH, de Koning HJ.

Int J Cancer. 2003 Jun 20;105(3):394-9.


Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.

Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ.

BJU Int. 2012 Dec;110(11):1654-60. doi: 10.1111/j.1464-410X.2012.11481.x. Epub 2012 Oct 8.


Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam).

Kerkhof M, Roobol MJ, Cuzick J, Sasieni P, Roemeling S, Schröder FH, Steyerberg EW.

Int J Cancer. 2010 Dec 1;127(11):2639-44. doi: 10.1002/ijc.25278.


Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.

Carlsson S, Assel M, Ulmert D, Gerdtsson A, Hugosson J, Vickers A, Lilja H.

Eur Urol. 2017 Jan;71(1):46-52. doi: 10.1016/j.eururo.2016.03.026. Epub 2016 Apr 13.


Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.

Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.

Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17.


Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.

van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, Schröder FH.

Eur J Cancer. 2010 Jan;46(2):377-83. doi: 10.1016/j.ejca.2009.09.008. Epub 2009 Oct 3.


Long-term prostate-specific antigen contamination in the Spanish arm of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Luján M, Páez Á, Angulo JC, Granados R, Nevado M, Torres GM, Berenguer A.

Actas Urol Esp. 2016 Apr;40(3):164-72. doi: 10.1016/j.acuro.2015.10.005. Epub 2015 Nov 24. English, Spanish.


A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.

Roobol MJ, Zhu X, Schröder FH, van Leenders GJ, van Schaik RH, Bangma CH, Steyerberg EW.

Eur Urol. 2013 Apr;63(4):627-33. doi: 10.1016/j.eururo.2012.07.029. Epub 2012 Jul 20.


Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.

Schröder FH, Bangma CH, Roobol MJ.

Eur Urol. 2008 May;53(5):901-8. doi: 10.1016/j.eururo.2008.01.048. Epub 2008 Jan 28.


What is an acceptable false negative rate in the detection of prostate cancer?

Verbeek JFM, Roobol MJ; ERSPC Rotterdam study group.

Transl Androl Urol. 2018 Feb;7(1):54-60. doi: 10.21037/tau.2017.12.12.


Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.

Roobol MJ, van Vugt HA, Loeb S, Zhu X, Bul M, Bangma CH, van Leenders AG, Steyerberg EW, Schröder FH.

Eur Urol. 2012 Mar;61(3):577-83. doi: 10.1016/j.eururo.2011.11.012. Epub 2011 Nov 15.


Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.

Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J.

Eur Urol. 2015 Sep;68(3):354-60. doi: 10.1016/j.eururo.2014.12.006. Epub 2014 Dec 31.


A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).

Randazzo M, Müller A, Carlsson S, Eberli D, Huber A, Grobholz R, Manka L, Mortezavi A, Sulser T, Recker F, Kwiatkowski M.

BJU Int. 2016 Apr;117(4):576-83. doi: 10.1111/bju.13310. Epub 2015 Oct 6.

Supplemental Content

Support Center